Company Analysis
Sign in

AgomAb Therapeutics NV (AGMB)

Nasdaq: AGMB · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2024
Full chart Alerts Compare
Grade5.2
◀ Past 5.9● Present 5.0▶ Future 5.0
8 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyas filed
Revenuen/a
Net incomen/a
Earnings per sharen/a
Operating cash flown/a
Cashn/a
Debtn/a
Shareholders’ equityn/a
Shares, dilutedn/a
Return on equityn/a
The recordfrom its filings
Filings in 202646
Newest filingNov 6 · 4
Annual reportApr 23, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$500,000
Patents granted2
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
The record holds no annual figures yet.
As filed, in USD. Nothing here is a forecast.

News

Nov 6, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 22, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 7, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 7, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 7, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 15, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 15, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton AGMB · research, not advice